Archive · 1 Nov 2025
Dr Reddy's Stock Dips Amid Health Canada's Non-Compliance Notice for Semaglutide
Imagine a company wants to sell a copy of a popular medicine.
They need to ask the government for permission, like filling out a special form.
Dr. Reddy's wanted to sell a copy of a weight-loss drug called Semaglutide in Canada.
They sent in a shortened application because they are using another company's research.
However, the Canadian health authorities said 'not yet' and issued a notice that the application isn't quite right.
Because of this, the company's stock price went down.
This drug is important for the company, and they hoped to be one of the first to launch it in many places.
Dr Reddy's stock fell 4% on Thursday.
The decline followed a notice of non-compliance from Health Canada for its ANDA of Semaglutide.
Semaglutide is a weight loss drug and a peptide.
An ANDA is a shortened application for a generic drug, relying on innovator research.
The non-compliance notice from Health Canada suggests the application requires further details or did not meet approval standards for this specific molecule.
- Who
- Dr Reddy's Laboratories, Health Canada
- What
- Dr Reddy's stock dropped after Health Canada issued a notice of non-compliance for its Abbreviated New Drug Application (ANDA) for the weight loss drug Semaglutide.
- When
- Thursday (specific date not provided, but article published Nov 1, 2025)
- Where
- Canada (Health Canada)
- Why
- Health Canada issued a notice of non-compliance for the ANDA, indicating the application for the generic drug Semaglutide requires further details or has not met compliance standards.
- Company
- Dr Reddy's Laboratories
- Stock Movement
- Down 4% on Thursday
- Regulatory Body
- Health Canada
- Application Type
- Abbreviated New Drug Application (ANDA)
- Drug
- Semaglutide (weight loss drug, peptide, GLP-1RA)
- Issue
- Notice of Non-Compliance